Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

News

Swiss Nordic Bio 2020

3 February 2020

Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet.

Swiss Nordic Bio 2020 will be held on 6 February in Zurich and is a collaboration between Vator Securities, the Embassy of Sweden, the Norwegian Embassy, Business Sweden and Business Finland.

Read More

Vator Securities advises SenzaGen on 106 MSEK Directed and Rights Issue

12 November 2019

The subscribers in the Directed Share Issue are, amongst other, AP-4 (The Fourth Swedish National Pension Fund), Ålandsbanken Abp, Consensus Asset Management, Kavaljer, Segersta and Thomas Olausson.

Read More

AlzeCure Pharma – A win for the amyloid hypothesis is a win for AlzeCure

24 October 2019

Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case.

The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta.

Read More

Vator Securities Sole Bookrunner in Nanoform SEK 106 million private placement

4 July 2019

Nanoform, an innovative medicine enabling nanotechnology company, announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.

Read More

Vator Securities advises Empros Pharma on 40 MSEK private placement

4 July 2019

Subscribers in the issue are both existing shareholders Thomas Eldered, Directors of the Board and Management as well as new shareholders with extensive investment experience from the Life Science sector. Thomas Eldered remains the main shareholder in the Company.

Read More

Vator Securities advises Xbrane Biopharma on 238 MSEK Directed and Rights Issue

2 June 2019

The subscribers in the Directed Share Issue are, amongst other, STADA Arzneimittel AG, NYIP (Nyenburgh Investment Partners), Swedbank Robur Medica, Belsize Asset Management GmbH and Serendipity Group AB.

Read More

Xlucane Product Launch Insight with STADA and Xbrane Biopharma

12 April 2019

Vator Securities hosted a Product Launch Insight event for Xlucane together with German STADA Arzneimittel and Xbrane Biopharma yesterday, 11 April 2019.

Read More

Vator Securities advises Xbrane Biopharma on SEK 59 million Rights Issue

29 March 2019

Vator Securities acted Financial Advisor in connection with the transaction raising SEK 59 million.

Read More